Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 3/20 | 0.57 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.47 |
| ▸ | HTR5A | P47898 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | NOS3 | P29474 | 1/20 | 0.45 |
| ▸ | NOS2 | P35228 | 1/20 | 0.45 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | GSK3A | P49840 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21591441 | 0.82 | CHRM2 (0.66) | NOS1CHRM2CYP1A2CYP2D6SCN8A | |
| SCHEMBL21591437 | 0.81 | NOS1 (0.54) | NOS1CHRM2CYP1A2CYP2D6SCN8A | |
| SCHEMBL12080831 | 0.81 | CHRM2 (0.54) | NOS1CHRM2CYP1A2CYP2D6SCN8A | |
| SCHEMBL4068320 | 0.80 | CHRM2 (0.68) | NOS1CHRM2CYP1A2CYP2D6SCN8A | |
| SCHEMBL16606319 | 0.78 | CHRM2 (0.68) | NOS1CHRM2CYP1A2CYP2D6CYP3A4 | |
| SCHEMBL4072845 | 0.77 | CHRM2 (0.73) | NOS1CHRM2CYP1A2CYP2D6SCN8A | |
| SCHEMBL3516997 | 0.77 | CHRM2 (0.52) | NOS1CHRM2CYP1A2CYP2D6SCN8A | |
| SCHEMBL10483879 | 0.76 | LOX (0.56) | CHRM2GSK3AGSK3B | |
| SCHEMBL6157520 | 0.76 | CHRM2 (0.71) | NOS1CHRM2CYP1A2CYP2D6TDP1 | |
| SCHEMBL10483974 | 0.75 | LOX (0.59) | CHRM2GSK3AGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12162863-B2 | Modulators of stimulator of interferon genes (STING) | Ryvu Therapeutics S.A. (PL) | 2024-12-10 | — | — | US | disclosed |
| US-20220402898-A1 | MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | Ryvu Therapeutics S.A. (PL) | 2022-12-22 | — | — | US | disclosed |
| EP-3807264-A1 | MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | Ryvu Therapeutics S.A. (PL) | 2021-04-21 | — | — | EP | disclosed |
| WO-2019238786-A1 | MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | Ryvu Therapeutics S.A. (PL) | 2019-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12162863-B2 | Modulators of stimulator of interferon genes (STING) | STING1, IRF3, CGAS | NOS1 13/4885CHRM2 1724/4885CYP1A2 718/4885 |
| US-20220402898-A1 | MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | STING1, IRF3, CGAS | NOS1 13/4885CHRM2 1724/4885CYP1A2 718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.